UA119783C2 - Комбінований препарат з антитілом до cd40 - Google Patents

Комбінований препарат з антитілом до cd40 Download PDF

Info

Publication number
UA119783C2
UA119783C2 UAA201701452A UAA201701452A UA119783C2 UA 119783 C2 UA119783 C2 UA 119783C2 UA A201701452 A UAA201701452 A UA A201701452A UA A201701452 A UAA201701452 A UA A201701452A UA 119783 C2 UA119783 C2 UA 119783C2
Authority
UA
Ukraine
Prior art keywords
antibody
antigen
tumor
binding region
specifically binds
Prior art date
Application number
UAA201701452A
Other languages
English (en)
Ukrainian (uk)
Inventor
Пітер Ельмарк
Питер Эльмарк
Пер НОРЛЕН
Пэр Норлен
Нійна Веітонмакі
Нийна Веитонмаки
Original Assignee
Аллігатор Біосайенс Аб
Аллигатор Биосайенс Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA119783(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1414270.7A external-priority patent/GB201414270D0/en
Priority claimed from GBGB1507541.9A external-priority patent/GB201507541D0/en
Application filed by Аллігатор Біосайенс Аб, Аллигатор Биосайенс Аб filed Critical Аллігатор Біосайенс Аб
Publication of UA119783C2 publication Critical patent/UA119783C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201701452A 2014-08-12 2015-08-12 Комбінований препарат з антитілом до cd40 UA119783C2 (uk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1414270.7A GB201414270D0 (en) 2014-08-12 2014-08-12 Antibodies
GB201422614 2014-12-18
GBGB1507541.9A GB201507541D0 (en) 2015-05-01 2015-05-01 Antibodies
PCT/EP2015/068598 WO2016023960A1 (en) 2014-08-12 2015-08-12 Combination therapies with anti cd40 antibodies

Publications (1)

Publication Number Publication Date
UA119783C2 true UA119783C2 (uk) 2019-08-12

Family

ID=53836090

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201701452A UA119783C2 (uk) 2014-08-12 2015-08-12 Комбінований препарат з антитілом до cd40

Country Status (25)

Country Link
US (3) US11149090B2 (enExample)
EP (3) EP3180087B1 (enExample)
JP (1) JP6654187B2 (enExample)
KR (1) KR102443258B1 (enExample)
CN (3) CN106573981A (enExample)
AU (1) AU2015303164B2 (enExample)
CA (1) CA2957146A1 (enExample)
CL (1) CL2017000335A1 (enExample)
CO (1) CO2017001317A2 (enExample)
CR (1) CR20170096A (enExample)
DK (1) DK3180087T3 (enExample)
EA (1) EA201790339A1 (enExample)
EC (1) ECSP17008984A (enExample)
ES (1) ES2725463T3 (enExample)
IL (1) IL250512B (enExample)
MA (1) MA47472A (enExample)
MX (1) MX382549B (enExample)
NI (1) NI201700015A (enExample)
PE (1) PE20170680A1 (enExample)
PH (1) PH12017500229A1 (enExample)
SG (1) SG11201701070WA (enExample)
SV (1) SV2017005380A (enExample)
UA (1) UA119783C2 (enExample)
WO (1) WO2016023960A1 (enExample)
ZA (1) ZA201701126B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149356A2 (en) 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
PT2953634T (pt) 2013-02-07 2021-09-02 Massachusetts Gen Hospital Métodos de expansão ou depleção das células t reguladoras
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
ES2746805T3 (es) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
AU2016263198C1 (en) 2015-05-15 2023-10-05 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3340999A4 (en) 2015-08-28 2019-06-12 The General Hospital Corporation AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES
SG11201804178YA (en) 2015-11-18 2018-06-28 Merck Sharp & Dohme Pd1 and/or lag3 binders
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
EP3455262A4 (en) * 2016-05-13 2020-04-08 The General Hospital Corporation ANTAGONISTIC ANTI-TUMOR NECROSE FACTOR RECEPTOR SUPER FAMILY ANTIBODIES
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
CA3030636A1 (en) * 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
EP3504239B1 (en) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
EP3532505A4 (en) 2016-10-25 2019-12-25 Urogen Pharma Ltd. BODY CAVES IMMUNODULATING TREATMENTS
EP3534951A4 (en) * 2016-11-02 2020-09-23 Apexigen, Inc. ANTI-CD40 ANTIBODIES IN COMBINATION AND METHOD OF USES
WO2018115051A1 (en) 2016-12-22 2018-06-28 F. Hoffmann-La Roche Ag Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
EP3569616B1 (en) * 2017-01-13 2021-09-29 Taizhou Hanzhong Biopharmaceutics, Inc. Monoclonal antibody against pd-1 and applications thereof
EP3589324A1 (en) * 2017-03-03 2020-01-08 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
WO2019025545A1 (en) 2017-08-04 2019-02-07 Genmab A/S BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
EP3675877A1 (en) 2017-08-31 2020-07-08 Multimmune GmbH Hsp70 based combination therapy
US20210283168A1 (en) * 2018-03-13 2021-09-16 Hibercell, Inc. Beta glucan and cd40 agonist combination immunotherapy
US20210386856A1 (en) * 2018-06-12 2021-12-16 Biontech Us Inc. Combination therapy with neoantigen vaccine
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
TWI803682B (zh) * 2018-08-20 2023-06-01 美商輝瑞股份有限公司 抗－ｇｄｆ１５抗體、組成物及使用方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽
EP3883600B1 (en) * 2018-11-23 2025-03-12 Strike Pharma AB Bi-specific conjugates
BR112021009835A2 (pt) * 2018-11-30 2021-08-17 Jiangsu Hengrui Medicine Co., Ltd. anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
AU2020284706A1 (en) * 2019-05-28 2021-12-16 Alligator Bioscience Ab Method of providing safe administration of an anti-CD40 antibody
EP4027998A1 (en) 2019-09-09 2022-07-20 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2023509902A (ja) * 2019-12-27 2023-03-10 インターオリゴ・コーポレイション 癌治療用免疫抗癌組成物
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CN113861292A (zh) * 2020-06-30 2021-12-31 百奥泰生物制药股份有限公司 抗cd40抗体或抗原结合片段及其应用
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
EP4415757A4 (en) * 2021-10-15 2025-10-08 Univ Rockefeller COMBINATION OF ANTI-CD40 ANTIBODIES AND IL-15 FOR THE TREATMENT OF CANCER
CN118201636A (zh) * 2021-10-26 2024-06-14 萨摩亚商柏沛生医股份有限公司 抗癌症及感染性疾病的组合疗法
CA3260666A1 (en) 2022-06-23 2023-12-28 Alligator Bioscience Ab Combination therapies
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1996006641A1 (en) 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
WO2002048351A2 (en) 2000-12-12 2002-06-20 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
EP1504098B2 (en) 2002-05-17 2011-02-09 Alligator Bioscience AB A method for in vitro molecular evolution of protein function
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
KR20070026522A (ko) 2004-04-27 2007-03-08 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 길항제 항-ｃｄ40 모노클론 항체 및 이들의 사용 방법
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
CA2609269C (en) 2005-05-26 2014-08-05 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
WO2009094391A1 (en) 2008-01-23 2009-07-30 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
CN102170908A (zh) * 2008-08-29 2011-08-31 莱顿大学医学中心附属莱顿教学医院 向个体的肿瘤引流淋巴结递送cd40激动剂
EP2478065B1 (en) * 2009-09-16 2016-04-13 E. I. du Pont de Nemours and Company Chiller apparatus containing trans-1,1,1,4,4,4-hexafluoro-2-butene and methods of producing cooling therein
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2014121099A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
JP6345787B2 (ja) 2013-12-20 2018-06-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗ａｎｇ２抗体とｃｄ４０アゴニストとの併用療法
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
SG11201708223QA (en) 2015-04-17 2017-11-29 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
RU2715597C2 (ru) 2015-05-29 2020-03-02 Эббви Инк. Антитела к cd40 и способы их применения
CN107771184B (zh) 2015-06-29 2022-11-01 百时美施贵宝公司 针对cd40的抗体
KR20180021833A (ko) 2015-06-29 2018-03-05 더 락커펠러 유니버시티 증진된 효능제 활성을 갖는 cd40에 대한 항체

Also Published As

Publication number Publication date
MA47472A (fr) 2019-12-18
PH12017500229A1 (en) 2017-07-10
NI201700015A (es) 2017-05-12
SG11201701070WA (en) 2017-03-30
US20170226217A1 (en) 2017-08-10
NZ729270A (en) 2024-03-22
US20240132609A1 (en) 2024-04-25
US12570753B2 (en) 2026-03-10
MX2017001864A (es) 2017-08-02
BR112017002729A2 (pt) 2018-02-27
EP3552665A2 (en) 2019-10-16
EP3180087B1 (en) 2019-03-13
KR20170041790A (ko) 2017-04-17
MX382549B (es) 2025-03-13
KR102443258B1 (ko) 2022-09-14
EP3180087A1 (en) 2017-06-21
CA2957146A1 (en) 2016-02-18
AU2015303164B2 (en) 2020-10-29
JP2017524715A (ja) 2017-08-31
IL250512B (en) 2021-08-31
EP4653463A2 (en) 2025-11-26
EP4653463A3 (en) 2026-02-25
CO2017001317A2 (es) 2017-08-10
US20210403589A1 (en) 2021-12-30
SV2017005380A (es) 2018-09-14
US20240228643A9 (en) 2024-07-11
DK3180087T3 (da) 2019-05-13
CL2017000335A1 (es) 2017-08-11
ECSP17008984A (es) 2017-05-31
IL250512A0 (en) 2017-03-30
EA201790339A1 (ru) 2017-06-30
PE20170680A1 (es) 2017-06-14
CN114099671A (zh) 2022-03-01
WO2016023960A1 (en) 2016-02-18
EP3552665A3 (en) 2019-12-18
JP6654187B2 (ja) 2020-02-26
ZA201701126B (en) 2025-08-27
US11149090B2 (en) 2021-10-19
ES2725463T3 (es) 2019-09-24
AU2015303164A1 (en) 2017-03-09
CN119280407A (zh) 2025-01-10
CR20170096A (es) 2017-06-15
CN106573981A (zh) 2017-04-19

Similar Documents

Publication Publication Date Title
UA119783C2 (uk) Комбінований препарат з антитілом до cd40
JP7209936B2 (ja) Ｍｓｌｎ標的三重特異性タンパク質及びその使用方法
CN111201038A (zh) Psgl-1拮抗剂及其用途
US11359008B2 (en) Compositions and methods for treating HIF-1a over-expressing cancers
WO2019189780A1 (ja) 癌の治療及び／又は予防用医薬組成物
JP2020519295A (ja) メソテリン結合タンパク質
KR20090026258A (ko) 신규 항ｃｄ98 항체
US20210137987A1 (en) Targeting of multiple antigens with multiplex car t cells in solid and liquid malignancies
JP2015512412A (ja) Ｄｒ５受容体アゴニストの組み合わせ
Capolla et al. A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles
US20160280789A1 (en) Methods for treating hematological malignancies
WO2016073647A2 (en) COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS
AU2020366205B2 (en) Methods and compositions for cancer treatment using nanoparticles conjugated with multiple ligands for binding receptors on NK cells
JP2025521028A (ja) 併用療法
BR112017002729B1 (pt) Terapia de combinação kit para tratar um tumor sólido em um indivíduo, anticorpo ou porção de ligação a antígeno do mesmo, uso e composição farmacêutica
TW202506190A (zh) 利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法
HK40072424A (en) Methods and compositions for cancer treatment using nanoparticles conjugated with multiple ligands for binding receptors on nk cells
HK40068835A (zh) 具有增强的t细胞介导的对肿瘤细胞的细胞毒性作用的针对chi3l1和pd1的双特异性抗体